* Liposome Co., of Princeton, N.J., said Abelcet, a lipid-based form of amphotericin B, has been approved in Norway as a second-line therapy for severe, invasive fungal infections. The drug will be marketed by Wyeth-Ayerst Nordiska, a subsidiary of American Home Products Corp., of Madison, N.J. Abelcet has been approved in 18 countries.

* MedImmune Inc., of Gaithersburg, Md., and its partner, BioTransplant Inc., of Charlestown, Mass., submitted an investigational new drug application with the FDA to begin clinical trials of MEDI-507, a humanized monoclonal antibody, for treatment of graft-vs.-host disease in organ transplant patients who are steroid-resistant. The antibody binds to the CD2 surface antigen receptor on T cells and natural killer cells to inhibit their harmful activity while allowing other immune cells to conduct normal protective duties. The drug also is targeted for clinical evaluation in psoriasis patients.

* Neurobiological Technologies Inc., of Richmond, Calif., said the company's stock listing has been moved from the Nasdaq National Market to the Nasdaq SmallCap Market. The company's symbol is NTIIC.

No Comments